The article recounts the Aligail Alliance lawsuit, which challenges the FDA’s policies on access to experimental drugs by dying patients outside of clinical trials, and discusses the many scientific and public policy issues that the suit raises.
The article recounts the Aligail Alliance lawsuit, which challenges the FDA’s policies on access to experimental drugs by dying patients outside of clinical trials, and discusses the many scientific and public policy issues that the suit raises.